Method of treating accommodation spasm

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology, physiotherapy. The method involves the exposure on an infraorbital region and surrounding regions. The exposure is ensured by pulse light, continuous emission and magnetic field. Wave length of the pulse light is 800-1200 nm, and wave length of the continuous emission is 630-670 nm. Average power of the pulse light is 3.0-10.0 mWt; pulse power is 2.0-4.0 Wt and pulse repetition frequency is 5.0 Hz - 10.0 kHz. Average power of the continuous emission is 50.0 Wt. Magnetic field strength is 20-45 mT. Said exposures are alternative or simultaneous. Supraorbital ridges, temporal and infraorbital regions are exposed. The exposure length is 1.0-5.0 minutes. Each session is preceded by instillation of trophic drops. The therapeutic course includes 7-15 sessions.

EFFECT: method prolongs the remission period ensured by cyliary spasmolysis.

2 cl, 3 ex

 

The invention relates to medicine, namely to methods for treating eye diseases, and can be used for treating spasm of accommodation.

Accommodation is the eye's ability to change his eyes to look into the distance and at close range. By reducing the ciliary muscle, which is suspended from the eye lens, is the focus of the object image on the retina. Long an eye on a close eye a distance of not physiological. When working on the computer with the visual load of more than 4 hours per day occurs spasm of the ciliary muscle. Given the global computerization, the treatment of spasm of accommodation is very important in our time.

Traditional methods of treatment are used:

1. Vision correction with glasses or contact lenses. This not only strengthens, but also exacerbates spasm of accommodation. The ciliary muscle is more spasseruetsya, the phenomenon of asthenopia and destructive changes intensify.

2. The zikloplegia - instillation midriatichesky drugs in the eye (Tropicamide, mydriacyl, phenylephrine, cyclomed).

When cycloplegia occurs partial withdrawal spasm and relaxation of the ciliary muscle. Duration instillation of drugs from 14 to 30 days, depending on the degree of spasm.

The disadvantages of this method:

- the inability to use, the working people;

- reduction of OS the company vision and increased photophobia during instillation of the drops;

- does not fully relax the ciliary muscle.

3. The lasik surgery is the evaporation sections of the cornea, resulting in a change of focus by reducing the thickness of the cornea.

The disadvantages of the method: the ciliary muscle remains spazmirovannah, produces a temporary result; when the visual load on near objects myopia remains; complications after surgery (early - keratitis, floater, remote - increased intraocular pressure, glaucoma)

4. Contact lenses

On the night of the cornea worn hard contact lenses, under the weight of which there is a flattening of the cornea and changing its curvature.

The disadvantage of this method is:

- the effect is temporary, per day, the cornea returns to its original position;

- trauma to the cornea.

- does not affect the pathogenetic side of the disease;

the absolute inefficiency of the method in the treatment of spasm of accommodation.

There is a method of treatment of eye diseases (strabismic amblyopia) [1], based on the effects of radiation of an argon laser operating in pulsed mode.

However, the known method does not allow to get rid of spasm of accommodation. The closest technical solution of the present invention is a method for the treatment and prevention of progression of blitar the bones in children [2], includes the combined effect of pulsed laser infrared (IR) radiation with λ=890 nm and a pulse power of 8-20 W, pulsed non-coherent infrared radiation with λ=860-960 nm with an average power of 60±30 mW, pulsed red light with λ=600-700 nm with a frequency of 2 Hz and static magnetic field with a magnetic induction of 35±10 MT at the occipital-parietal region of the head, the neck, the carotid sinuses and biologically active points (BAP), occipital-parietal region of the scalp from the coronal suture parietal bone to the hole on the middle line aponeurosis effect laser IR-radiation with a pulse power of 20 W, with the frequency of the pulsed laser and non-coherent IR radiation 1000 Hz scanning movement downward exposure duration 2-4 min, then exposed at the bottom edge of the occipital bone between the tendons cleveley and trapezius muscles of the two sides of infrared laser radiation pulse power 8 W, pulse frequency of laser and non-coherent infrared radiation 50 Hz exposure for 2 min on one field, then affect the carotid sinuses on both sides with a pulse power of the laser PC-radiation 8 watts, with the frequency of the pulsed laser and non-coherent IR-radiation 50 Hz exposure for 2 min, then act on symmetric BAT power laser IR from the teachings of 8 W with the frequency of the pulsed laser and non-coherent IR radiation 1000 Hz, initially, at the point of common steps: F 2F3F36, Gi4, IG3TR10V62then with a pulse power of the laser IR-radiation 8 watts, with the frequency of the pulsed laser and non-coherent IR radiation 5 Hz to point local actions around the eyes: E1E2, R23VB1V1V2, W6and auricular points: al8, Al24A, Al24, exposure 20-30 s at each point in the exposure duration 6-9 min, the treatment is 8-12 sessions.

The known method provides polyfactorial (combined), simultaneous exposure to different types of radiation: pulsed infrared laser radiation, pulsed broadband infrared radiation, pulsating red radiation, and a constant magnetic field.

However, using only pulsed radiations is not possible to fully ensure the high efficiency of treatment and to achieve stability and long-term treatment outcome in the treatment of spasm of accommodation for each case due to non-use of the capabilities of the combined effect of continuous emission and additional drugs.

Task to be solved by the claimed invention is directed, is to improve the effectiveness of treating spasm of accommodation.

The technical result for localsize in improving the stability and sustainability of the treatment, is achieved in the proposed method for the treatment of spasm of accommodation, including the impact on the infraorbital region and the adjacent region of the field of pulsed radiation and magnetic field, those that have the combined effect of pulsed radiation with a wavelength of 800-1200 nm and continuous radiation with a wavelength of 630-670 nm, the effect of exercise pulsed radiation with an average power of Pcrimp=3,0-10,0 mW pulse power Puti=2,0-4,0 W and pulse repetition frequency futi=5,0 Hz-10.0 kHz, the influence of continuous radiation is carried out with an average power of Psrnapto 50.0 mW, and the magnetic field is carried out at the intensity H of the magnetic field in the range N=20-45 MT, and referred to the joint action carried out successively or simultaneously in the areas of the brow, in the temporal and infraorbital region, the exposure time Tdin these zones is kept in the range of Td=1,0-5,0 min, at the same time before each session the patient navigate the instillation trophic drops, and in one treatment from 7 to 15 sessions.

This repetition of the treatment carried out through 1.0 to 2.5 months. The proposed method is as follows.

For hardware effects were used apparatus of quantum therapy type apparatus is ATA "RIKTA" with enhanced functionality (analog devices [3]). Before each session the patient is in the horizontal position and he takes the instillation trophic drops.

Then at the infraorbital region and surrounding areas (zones brow and in the temporal region) impose elements of the excitation radiation that is connected to the apparatus, and set using the controls necessary mode of its operation. The elements of the excitation radiation have alternately or simultaneously.

When the apparatus is combined joint impact on the infraorbital region and the adjacent region of the electromagnetic radiation, magnetic field and medicines. When this impact is simultaneously pulsed radiation with a wavelength of 800-1200 nm and continuous radiation with a wavelength of 630-670 nm.

Pulsed radiation create with an average power of Pcrimp=3,0-10,0 MW pulse power Puti=2,0-4,0 W and pulse repetition frequency futi=5,0 Hz-10.0 kHz. Continuous radiation create with an average power of Psrnapto 50.0 MW. The exposure time Tdin these zones is kept in the range of Td=1,0-5,0 minutes

The intensity H of the magnetic field provide in the range N=20-45 MT.

Depending on the condition of the patient in a single treatment from 8 to 12 sessions. Repeat what their course of treatment are carried out through 1.0 to 2.5 months. Electromagnetic radiation apparatus acts as a "pulse therapy", which relieves spasm of the ciliary muscle, restoring its normal state. This instillation trophic drops before each session (taufon, emoxipin) when exposed to electromagnetic radiation allows the drops to penetrate to the deep layers, which increases the effect as from drops and from electromagnetic radiation.

In the known traditional methods of treatment drops are only up to the middle layers of the eye, and their effect on the deeper layers is not shown.

The selected localization of elements of the excitation electromagnetic radiation allows the radiation apparatus not only to relieve spasm of the ciliary muscle, but also significantly improve the hemodynamics of the eye, because these elements are projections of the ciliary muscle and circular muscle of the eye. Thus spasm is removed from the ciliary muscle and cleaned the phenomenon of asthenopia. Thus, breaking the vicious circle that causes this disease.

The proposed method can achieve high efficiency in the treatment. The pulses from the ciliary muscles do to the brain is restored and binocular vision, improves hemodynamics and trophic eyes.

Example 1

Patient K., aged 41 years.

Complaints: discomfort in the eyes, blurred distance vision, eye fatigue.

right eye 0.5;

left eye 0.5;

Anterior - without features. Refractive transparent environment.

The fundus of the eye: optic disc pale, clear boundaries, the ratio of arteries and veins 1/2, tortuous vessels, uneven caliber. Retin Semizorova.

Diagnosis: spasm of accommodation, computer vision syndrome.

Treatment: Before each session, the patient carried out the instillation of drops taufona 2-5%. The elements of the excitation electromagnetic radiation disposed in areas of the brow, in the temporal and infraorbital region.

Installed the following hardware:

- pulse radiation λuti=800-1200 nm, Rcrimp=3.0 mW, Ruti=2.0 W, futi=10,0 Hz;

- continuous radiation λcont.=630-670 nm, Rsrnap30,0 mW;

- the magnetic field strength H=20-45 MT;

- the exposure time Td=5,0 minutes

Visual acuity after treatment:

- right eye 1.0;

- left eye 1.0.

Artery less spazmirovanne and tortuous, with vessels more fully.

In the course of treatment conducted 10 sessions. Appointed repeat treatment after one month. After the course the hardware treatment - resistant restore the view to 100%.

Completely passed phenomena asthenopia, retin-a more full-blooded.

Example 2

Patient H., age 32 years.

Visual acuity to l the treatment:

- left eye 0.5;

- right eye 0.7.

Complaints: discomfort in the eyes, decreased vision in the distance, expressed weariness at the end of the day.

Anterior segment without features. Refractive transparent environment.

The fundus of the eye: optic nerve head grayish, clear boundaries, the ratio of arteries and veins 1/4.

Arteries narrowed significantly, Vienna full, tortuous vessels, uneven caliber. The retina - severe ischemia.

Treatment: Before each session, the patient carried out the instillation of drops emoxipin 0.5 to 2.0%. The elements of the excitation electromagnetic radiation disposed in areas of the brow and infraorbital region.

Installed the following hardware:

- pulse radiation λuti=800-1200 nm, Rcrimp=5.0 mW, Ruti=2.5 W, futi=5.0 kHz;

- continuous radiation λcont.=630-670 nm, Rsrnap=40.0 mW,

- the magnetic field strength H=20-45 MT.

- the exposure time Td=4,0 minutes

Examination after the course of treatment hardware

Visual acuity:

- right eye 0.6;

- the left eye of 0.8.

Retin-a more than worthwhile. The ratio of the arteries to the veins 1/3.

After a course of treatment hardware eyesight has improved significantly, the phenomenon of asthenopia disappeared.

In the course of treatment conducted 8 sessions.

Appointed repeat treatment through 2.0 IU is Aza.

Example 3

Patient E., 27 years.

Complaints: the deterioration of the distance vision, eye fatigue, redness, pain in the eyes.

Visual acuity before treatment:

- left eye 0.7;

- right eye 0.7.

Complaints: discomfort in the eyes, decreased vision in the distance, expressed weariness at the end of the day.

Anterior segment without features. Refractive transparent environment.

Glazou bottom: ischemia, the ratio of arteries and veins 1/2.

Treatment: Before each session, the patient carried out the instillation taufona 2-5%. The elements of the excitation electromagnetic radiation disposed in areas of the brow, in the temporal and infraorbital region.

Installed the following hardware:

- pulse radiation λuti=800-1200 nm, Rcrimp=10,0 mW, Ruti=4.0 watts, Tuti=10.0 kHz;

- continuous radiation λcont.=630-670 nm, Rsrnap=50.0 mW,

- the magnetic field strength H=20-45 MT.

- the exposure time Td=2,0 min.

Examination after the course of treatment hardware

Visual acuity:

- right eye 0.8;

- the left eye of 0.8.

Retin-a more than worthwhile. The ratio of the arteries to the veins 1/3.

The phenomenon of asthenopia disappeared, positive dynamics.

Appointed repeat treatment after 2.5 months.

Observation of patients showed that the proposed method allows to:

- fix when the inu occurrence of spasm of accommodation;

- return of the ciliary muscle to its original state;

to improve hemodynamics;

- improve the trophic eyes;

to improve visual acuity;

to achieve stability and sustainability of the treatment.

The treatment was carried out using the apparatus of quantum therapy with enhanced functionality, allowing you to set the modes of electromagnetic radiation in a wider range of options, allowing to choose the optimum conditions for each particular patient.

Sources of information

1. USSR author's certificate No. 1769879, IPC 61F 9/00 from 23.10.1992.

2. RF patent №2265464, IPC 61N 5/06 dated 14.12.2004.

3. http://www.peresvetmed.ru/rikta_milta_devices.html.

1. A method of treating spasm of accommodation, including the impact on the infraorbital region and the adjacent region of pulsed radiation and magnetic field, characterized in that have the combined effect of pulsed radiation with a wavelength of 800-1200 nm and continuous radiation with a wavelength of 630-670 nm, the effect of exercise pulsed radiation with an average power of Pcrimp=3,0-10,0 mW pulse power Puti=2,0-4,0 W and pulse repetition frequency futi=5,0 Hz-10.0 kHz, the influence of continuous radiation is carried out with an average power of Psrnapto 50.0 mW, and the magnetic field carried the t with intensity H of the magnetic field in the range N=20-45 MT, and referred to the joint action carried out successively or simultaneously in the areas of the brow, in the temporal and infraorbital region, the exposure time Tdin these zones is kept in the range of Tdin these zones is kept in the range of Td=1,0-5,0 min, at the same time before each session the patient navigate the instillation trophic drops, and in one treatment from 7 to 15 sessions.

2. The method of treatment according to claim 1, characterized in that the repetition rate of the treatment carried out through 1.0 to 2.5 months.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

EFFECT: there are produced new benzimidazole derivatives showing PPARγ modulatory activity.

41 cl, 2 dwg, 6 tbl, 76 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel substituted pyrimidine derivatives, possessing properties of inhibiting activity of receptor of kinase insertion domain (KDR), or their pharmaceutically acceptable salts. In formula (1): each of X and Y independently represent O, NR, where R represents H; Z represents CR', where R' represents H or halogen; V, U and T together represent or each of R1, R2, R3, R4 and R6 independently represent H, halogen, cyano, C1-10alkyl; R5 values are given in the invention formula; R7 represents C1-10alkyl.

EFFECT: invention also relates to method of treating angiogenesis-associated disorder such as cancer or age-related macular degeneration.

16 cl, 318 ex

Eye drops // 2453304

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, namely to drugs presented in the form of a solution and applicable for therapeutic purposes, particularly treating eye diseases. Eye drops for inflammatory eye diseases characterised by the fact that they contain benzalkonium chloride, sodium hydrogen phosphate dodecahydrate, disodium edetate, sodium chloride, sodium hyaluronate, potassium dihydrogen phosphate, Polysorbate, linden blossom infusion, camomile blossom infusion, water for injections in certain proportions and pH 4.5-11.4.

EFFECT: eye drops provide deposition, uniform absorption of the active ingredients over a period of time between installations, eye tissue tolerance and finally substantially expanded possibility of therapeutic application; besides, prolonged action of an antihistaminic preparation and a vasoconstrictive agent and availability of a hypoallergic preservative are ensured.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology and clinical pharmacy, and is applicable for visual organ and facial skin sanitation in purulent conjunctivitis, eyelid adhesion and dacryolith formation. The invention consists in the fact that an agent represents an antiseptic water solution consisting of 0.55-1.0 % hydrogen peroxide, 1.0-1.5 % sodium hydrocarbonate and 0.5-1.0 % lidocaine hydrochloride.

EFFECT: invention provides effective and safe conditions for the conjunctival cavity, eyelash, eyelid, surrounding face sanitation.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, particularly to ophthalmology. An ophthalmic device comprises a polymer matrix which in turn contains a biologically active agent and a carrier. The ophthalmic device is applicable for release of the biologically active agent induced by one or more amounts of lachrymal components from the polymer matrix in contact with tears in an eye. A method for making the ophthalmic device involves mixing a matrix-forming substance, the carrier and the biologically active agent, introducing a mixture into a cast for making the device and polymerising the matrix-forming substance in the cast. A method for biologically active agent delivery to a subject involves subject's eye contact with the device wherein one or more amounts of the lachrymal components release the biologically active agent from the device.

EFFECT: invention provides the stable ophthalmic device which is effective to deliver the biologically active agents into patient's eyes for long periods of time.

19 cl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to ophthalmology. A drug preparation stimulates proliferation of epithelial cells of a tarsal gland or epithelial cells of a cornea. The drug preparation contains [3-[2-[4-isopropyl-2-(4-triflouromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-triflouromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chloriophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy] acetic acid, or their pharmaceutically acceptable salt as an active ingredient. Said active ingredient is applied for making the drug preparation, and as stimulating proliferation of epithelial cells of the tarsal gland or epithelial cells of the cornea.

EFFECT: group of inventions provides treating eye diseases, such as xerophthalmus, tarsal gland dysfunction, corneal epithelial diseases.

18 cl, 3 dwg, 4 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology and may be used to treating spastic squint and atypincal squint accompanying type 1 Duane syndrome. It involves exposing a lateral end of an internal rectus muscle, further at 2-3 mm from an attachment point of the muscle to sclera a needle is inserted in an end face of the lateral muscle; the needle is moved at 8-10 mm along the muscle in a distal direction at an angle from the lateral end of the muscle to its middle axial border, and the preparation Disport 15-20 units is introduced. The incisional wound is closed. The similar method is used for surgical manipulations on the internal rectus muscle of the other eye, if the patient suffers from spastic squint and double Duane syndrome.

EFFECT: method provides reduced dynamometric functions of the internal rectus muscles and compensated optimal balance in the oculogyric system.

2 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of formula I or their pharmaceutically acceptable salts showing an ability to inhibit sphingosine kinase, to a based pharmaceutical composition, to a method of inhibiting sphingosine kinase and a method of treating diseases specified in breast cancer, diabetic retinopathy, arthritis and colitis. , wherein X represents -C(R3,R4)N(R5)-, -C(O)N(R4)-; R1 represents phenyl unsubstituted or substituted by 1 or 2 halogens. The values of R2, R3, R4, R5 substitutes are such as specified in the patent claim.

EFFECT: preparation of new compounds.

17 cl, 24 dwg, 9 tbl, 26 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely ophthalmology, and may be used for treating dry eye syndrome and recovered function of lachrymal fluid secretion in a mammal. For this purpose, a composition containing a pharmaceutically effective amount of a Janus kinase 3 inhibitor of the following structure is introduced in a mammal: 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d] pyrimidin-4-yl) amino] piperidin-1-yl}-3-oxopropionitryl.

EFFECT: introduction of the Janus kinase 3 inhibitor enables considerable increase of the secreted lachrymal fluid volume.

11 cl, 2 tbl, 6 ex, 8 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology, and can be used for ensuring regression of ocular neovascularisation. That is ensured by introducing a composition containing a therapeutically effective amount of a receptor tyrosine kinase inhibitor which blocks tyrosine autophosphorylation of VEGF receptor-2 with IC50≤ 10 nM and VEGF receptor-1 with 1C50≤ 10 nM and PDGFR with 1C50≤ 100 nM.

EFFECT: invention provides strong antiangiogenic effectiveness, ensured avoiding visual acuity loss related to ocular neovascularisation.

7 cl, 5 tbl, 8 ex, 9 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely physiotherapy, and may be used for laserophoresis of biologically active substances of higher molecular weight. What is used is a low-intensity laser emission (LILE) by alternating various wave lengths and power densities every second day. At wave length 632-638 nm, power density makes 10-40 mWt/cm2. At wave length 780-785 nm, power density makes 20-90 mWt/cm2. Length of the exposure on one area makes 0.5-1 minute. Length of one session does not exceed 15 minutes.

EFFECT: implementing the method provides higher volumes of the substance of higher molecular weight introduced by laserophoresis in treating various dermatological diseases and eliminating cosmetic defects ensure by more optimal distribution of the introduced substance in biotissues.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and may be used in neurology, traumatology, physiotherapy, orthopaedics, in stepped therapy of protrusions, herniated disks, scoliosis, kyphosis, kyphoscoliosis, spondylolisthesis, osteochondrosis, myofascial syndrome, myositis, vertebrogenic (discogenic) torticollis, intercostal neuralgia, lumbago, lumbar ischialgia. The I stage consists in intravenous blood exposure to UV and red low-intensity laser emission, graduated uniform extension of all spinal segments in a traction apparatus with no fixation devices with considering patient's anthropometric data in complete muscular relaxation. The stage II consists of two alternating series of procedures. The series I implies paravertebral vacuum cup massage from both side upwards from a lumbar to cervical spine along massage lines of the back with a cup tightly pressed to skin. It is followed with vacuum gradient therapy with using a number of cups of different volumes and sections simultaneously along a venous outflow. Further, a leech therapy (LT) covering an umbilicus, a swing therapy (ST) in the SWING MACHINE training facility. The series II includes a one-day acupress therapy of the spinal muscular frame with using ebonite rollers along massage lines of the back, then - manual exposure on its musculo-ligamentous apparatus and joints in the form of various massage types, a yumeiho therapy, a postisometric relaxation, further the LT and the ST on the back area. The days free from the manual exposure and the LT on the back area; the ST is followed by physical exercises based on the system of traditional Cigun, Nishi, yoga techniques The stage III provides diagnosis and orthopaedic feet correction.

EFFECT: therapeutic effect is ensured by exposure on all the pathogenesis patterns of the spinal diseases: cell, immune, humoral, neuromuscular, mechanical, reflex, at the level of the integrated system, including principal drug-free recovery of the spinal health.

6 cl, 5 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology and radiology and consists in carrying out complex treatment by installation of endobronchial reverse valve into bleeding bronchus. At this background performed is external beam radiotherapy (EBRT) TFD 40 Gy, with radiomodifier: 5 fluorouracil - 250 mg, course dose - 4-5 g, or cysplatin - 10 mg, course dose - 120 mg, which are introduced daily, intravenously 30 minutes before the beginning of EBRT session. 14 days after completion of the first stage of EBRT fibrobronchoscopy (FBS) is performed with removal of bronchoblocker, and the second stage of EBRT TFD 30 Gy is performed to total dose for two stages EBRT TFD 70 Gy, with application of the same radiomodifiers in the same mode. 30 days after finishing EBRT FBS is made and is tumour remains in bronchus lumen or there is a suspicion of it, photodynamic preparation is introduced intravenously, and after 4 hours FBS and laser irradiation of tumour are carried out. Control examination of tracheobroncial tree is carried out after 30 days and after 26 months.

EFFECT: method ensures increase of life expectancy and improvement of its quality for patients with non-operable lung cancer complicated by hemorrhage.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology, venereology and immunology, and is applicable for local immunocorrection of female infectious-inflammatory urogenital diseases caused by sexually-transmitted microorganisms. For this purpose, with underlying drug-induced therapy, the immunomodulatory therapy is used from first day of therapy by magnetic laser exposure on a uterus neck. The uterus neck is exposed by a gynecologic speculum which is removed after the procedure is completed. The magnetic laser exposure immediately covers a cervical canal. That is ensured by using a low-intensity laser with variable pulse generation. The magnetic field intensity makes 1.25 T. Pulse train frequency per minute is 30. A pulse interval is 100 msec. Length of the exposure is 5 minutes. The therapeutic course is 10 procedures.

EFFECT: method provides higher complex clinical effectiveness ensured by normalising local immunity factors, namely functional activity recovery of neutrophilic granulocytes of the cervical canal, higher concentration of pro-inflammatory cytokines, immunoglobulins A, M, G in the cervical canal.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and veterinary science. A method involves sequential intravenous introduction of a binary catalytic system (BCS): an oxidation catalyst - a metal complex and an oxidation substratum - ascorbic acid (AA). The oxidation catalyst is introduced in a maximally tolerable or lower doses, and AA - in doses related to molar ratio of the metal complex: AK=1:10. The method also involves local hyperthermia of the tumour with using near infra-red laser emission. The tumour temperature is maintained within the range of 43-45°C by adjusting laser power density. The emission is terminated after achieving the minimum power density maintaining the tumour temperature within the preset temperature range. The declared device comprises a near infra-red laser with emissive power switch-on, switch-off and adjustment systems, and optical system of laser beam formation, a tumour temperature control system with its output connected both with an input of a laser negative feedback system, a laser power density control system. The device comprises an additionally adjustable power density discriminator. An input of the laser power density discriminator is connected with an output of the laser power density control system. The output of the discriminator is connected to an input of the laser switch-off system.

EFFECT: invention provides higher clinical effectiveness.

5 cl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dermatovenerology and is applicable for treating chronic infectious urethritis complicated by prostatitis. That is ensured by taking azithromycin 1.0 g (sumamed) once a day in 1st-7th-14th days combined with the complex therapy. The complex therapy involves rectal suppositories Dalargex, 1 suppository daily at bedtime No.10, prostate massage, rectal laser therapy and daily application of fluoroquinolone - gemifloxacin (factive) 1 tab. (320 mg) a day for 14 days.

EFFECT: method enables prolonged remission of the disease, higher life quality of the patients, recovers the reproductive function due to improved eradication of the opportunistic flora in the prostate secretion contents.

4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely urology, is applicable for treating chronic cystitis. That is ensured by drug instillations into a bladder. In addition, the instillation is preceded by endovesical mucosal exposure to laser light of wave length 0.62 mcm. The instillation is followed by pubic exposure to laser light of wave length 0.86 mcm within a projection of the bladder. The duration of each procedure is 7 minutes; the therapeutic course is 10-12 procedures.

EFFECT: method provides higher clinical effectiveness ensured by pain pulse interruption and improved microcirculation and consequently prolonged drug staying in the bladder cavity as a result of the exposure to laser light before the instillation, and also by deeper drug penetration in bladder tissue as a result the epicutaneous exposure to laser light after the instillation.

1 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely therapy, and is applicable for correction of cardiovascular disorders accompanying metabolic syndrome in the patients suffering osteoarthrosis. It involves the supravenous blood exposure at wave length 405 nm, light guide tip power 1.5 mWt, length of a procedure 5 minutes. It is followed by contact joints exposure at wave length 630 nm, pulse power 10 Wt, frequency 80 Hz. Knee joints are exposed for 2 minutes from 4 sides and with using a lability technique by beam scanning along an joint space for 2 minutes. Hip joints are exposed through a projection of inguinal ligament, greater trochanter, ischial tuberosity for 2 minutes and with using a lability technique by beam scanning along the joint space for 4 minutes. The therapeutic course includes 10 daily sessions.

EFFECT: method allows providing prolonged remission and lowered drug load ensured by eliminating inflammatory activity, lipid spectrum, coagulation hemostasis and carbohydrate metabolism disorders.

19 tbl

FIELD: medicine.

SUBSTANCE: invention refers to physiotherapeutic apparatuses and is applicable for vitality recovery after damaging exercises and mental overload, and for treating various diseases by laser reflex therapy. A presented apparatus comprises a handle body which integrates a laser diode coupled with a control unit with emission brought outside through an outlet on a pointed handle tip. A side surface of the handle comprises a general electrode also connected with the control unit. The control unit is connected to a power supply unit. In the presented apparatus, the power supply unit and the control unit are integrated in the handle, on an internal side surface of the outlet, there is an acupuncture point detector represented by a thin metal core of the diameter no more than 1 mm one end of which is bent so that it gets into a laser beam, and another one is connected to the control unit.

EFFECT: invention allows detecting the acupuncture points more precisely with using a laser beam.

1 dwg

FIELD: medicine.

SUBSTANCE: claimed invention relates to ophthalmology, namely to ophthalmic oncology and is intended for organ-preserving treatment of intraocular tumours. Transpupillary PDT is performed. After 3-20 days treansscleral PDT is carried out. After tumour devitalisation, total vitrectomy and endoresection of tumour is performed. Vitreous cavity is filled with substitute of vitreous body and laser coagulation of retina is carried out.

EFFECT: method ensures radical complete destruction of tumour with extension of indications to organ-preserving treatment with recovery of functional reserves of eye.

3 ex

FIELD: medicine.

SUBSTANCE: invention is referred to the area of medicine, namely to ophthalmology and physical therapy. The method involves exposure of eye tissues to electromagnetic radiation and magnetic field. The exposure is performed using impulse radiation with the wavelength 800-1,200 nm, continuous radiation with the wavelength 630-670 nm and magnetic field with intensity 20-45 mTl. The pulse radiation used has average radiant power 1.5-4.0 mW, impulse power 1.0-3.0 W, pulse repetition frequency 50 Hz. Constant radiation has average radiant power up to 40.0 mW. The exposure to electromagnetic radiation and magnetic field is performed for 5.0-10.0 minutes.

EFFECT: method provides for stable and long term treatment results.

2 ex, 3cl

Up!